QCast Episode 71: What is a Clinical Development Plan?

A clinical development plan, or CDP, turns a development strategy into a connected programme of studies, decisions and regulatory interactions. In this QCast episode, co-hosts Jullia and Tom consider how the target product profile and existing evidence should shape study objectives, patient populations, endpoints and dosing decisions. They also explain why the plan needs to remain useful as new clinical data changes the programme’s assumptions.

The practical challenge is keeping those elements connected. A study can run successfully and still leave the programme with an unresolved evidence gap. Vague go or no-go criteria can also make results harder to interpret, while unrealistic timelines may overlook the people, sites, systems or drug supply needed to deliver the work. A useful clinical development plan makes these dependencies visible and gives teams a defined basis for deciding whether to progress, adapt or stop.

🎧 Listen to the Episode:

Key Takeaways

Define the evidence need before designing the study

Each study should address a specific gap between what is already known and what the intended product profile requires. This affects choices such as the study population, endpoints, comparator, dose and schedule. If the team cannot explain which decision a study result will support, the study’s place in the programme needs further review.

Set decision criteria before results are available

A useful decision point identifies what will be assessed, the threshold for success and the action attached to each credible outcome. This reduces the scope for subjective interpretation once the data are available. It can also accommodate uncertainty by defining alternative paths for outcomes such as an unexpected safety profile or an effect concentrated within a patient subgroup.

Build regulatory, risk, and resource planning into the CDP

Regulatory interactions should have a defined purpose and be timed so that the necessary evidence and internal decisions are ready. Identified risks should connect to monitoring, stopping rules and review responsibilities, while programme timelines should reflect available staff, sites, systems, manufacturing capacity and budget. Ownership, version control and reviews after major programme events help keep these assumptions aligned with the latest evidence.

Full Transcript

Jullia

Welcome to QCast, the show where biometric expertise meets data-driven dialogue. I’m Jullia.

Tom

I’m Tom, and in each episode, we dive into the methodologies, case studies, regulatory shifts, and industry trends shaping modern drug development.

Jullia

Whether you’re in biotech, pharma or life sciences, we’re here to bring you practical insights straight from a leading biometrics CRO. Let’s get started.

Tom

When people hear the term clinical development plan, what should they be picturing?

Jullia

They should think of it as the shared roadmap for the clinical programme. It connects the evidence you need to generate with the studies, decisions, timelines and resources required to generate it. And it needs to stay useful throughout development, rather than simply recording what the team believed at the beginning.

Tom

You’ve described it as a roadmap, but clinical development strategy is often described in similar terms. Where’s the distinction?

Jullia

The strategy defines what the programme needs to prove, to whom and with what level of risk. That includes the target population, the unmet need, the endpoints likely to be relevant and the markets the sponsor intends to pursue. The plan takes those choices and turns them into a sequence of studies, regulatory interactions and decision points.

Tom

So, if the strategy isn’t clear, can a detailed plan still compensate for that?

Jullia

Not really. You can have a very detailed schedule and still be heading in the wrong direction. Without a clear strategy, studies can accumulate because they seem reasonable individually, but the evidence they generate may not add up to a convincing case for approval or support the intended product profile.

Tom

Where does the target product profile fit into that thinking?

Jullia

The target product profile, or TPP, gives the programme a reference point. It describes the intended indication, patient population, treatment setting, dosing approach, efficacy expectations and acceptable safety characteristics. Those expectations then shape choices such as who enters the trials, which endpoints are measured and what comparator is appropriate.

Tom

Could you give a simple example of a decision that traces back to the TPP?

Jullia

Yes, so take the intended dosing schedule. If the TPP assumes a particular route and frequency of administration, the clinical programme needs enough evidence to support that use. An early dose-ranging study may therefore need to assess more than whether the treatment has an effect. It may also need to show which dose and schedule offer an acceptable balance of efficacy, safety and tolerability before the programme moves into a larger trial.

Tom

And once the TPP is defined, is the next step to start designing the individual studies?

Jullia

Almost, but there’s an important step before that, which is assessing the evidence gaps. The team looks at what’s already known from non-clinical findings, existing clinical data and relevant scientific knowledge, then compares that with what the intended product profile requires. That helps prevent the study design from getting ahead of the underlying evidence question. Each study should close a defined evidence gap or support a decision the programme needs to make.

Tom

What can go wrong when a team skips that assessment?

Jullia

They may design a Phase 2 study around an endpoint that doesn’t fully support the later regulatory objective, or recruit a population that’s broader than the one most likely to benefit. The immediate study might still run successfully, but the result may leave an important question unresolved. That can lead to another study, a protocol redesign or a delay before the next phase.

Tom

Once the gaps are clear, what level of detail belongs in the plan?

Jullia

Enough detail to understand the purpose and relationship of each study. For each phase, you’d normally set out the objective, population, endpoints, approximate sample size and the main operational assumptions. You also need to show how the result from one study informs the next, rather than presenting the trials as separate pieces of work.

For example, an early study might establish safety, tolerability and an appropriate dose range. A proof-of-concept study then looks for an initial efficacy signal in the target population. The result might determine whether the programme stops, continues as planned or refines the population before dose optimisation and confirmatory development.

Tom

That brings us to decision points. A lot of plans include go or no-go milestones, but how specific do those need to be?

Jullia

They need to define what will actually be assessed and what happens after each possible outcome. A useful decision point identifies the metric, the success threshold, the statistical criteria behind it and the resulting action. Saying the team will look for an encouraging efficacy signal leaves too much open to interpretation once the data is available.

Tom

Let me challenge that slightly. Early development involves uncertainty, so can very specific criteria make the team too rigid?

Jullia

They can if they’re written without sensible alternatives. Pre-specification doesn’t mean pretending uncertainty has disappeared. Rather, it means agreeing how the evidence will be judged, recording the assumptions behind the preferred path and identifying what the team might do if recruitment, safety or efficacy differs from expectations.

Tom

So the plan can allow adaptation without moving the goalposts after seeing the result?

Jullia

Yes, see, the programme may have a planned route, but it should also define credible alternatives. For example, a study might meet its safety criteria but show that the treatment effect is concentrated in a particular patient subgroup. The team can then assess whether population refinement is scientifically and statistically justified, rather than making an unstructured decision under pressure.

Tom

How early should regulatory planning enter the conversation?

Jullia

Early enough to influence the evidence plan, because endpoint choices, patient populations and study designs can be expensive to change later. The clinical development plan, or CDP, should anticipate the relevant regulatory pathway in each target market, the authority interactions the programme is likely to need and the submissions those interactions support. Different jurisdictions may offer different mechanisms, so they need to be assessed individually rather than treated as interchangeable.

Tom

And those authority interactions aren’t simply dates on a timeline, are they?

Jullia

No. Each interaction should have a clear purpose. The team may need advice on an endpoint, agreement on a development approach or feedback before moving into confirmatory trials. The briefing materials and internal decisions need to be ready in time for that discussion, so regulatory planning has direct consequences for the study and analysis timelines.

Tom

Risk planning can sometimes sit in a separate document or workstream. How closely should it connect to the CDP?

Jullia

It should be embedded in it. Product safety risks need to be considered alongside risks to participant protection, endpoint reliability and the integrity of critical data and processes. If a potential safety signal is identified from the mechanism of action or non-clinical work, the plan should connect that risk to monitoring, dose-escalation controls, stopping rules and clear responsibility for review.

Tom

What might that look like during day-to-day trial activity?

Jullia

Suppose an adverse event is entered at a site and meets a pre-agreed trigger for medical review. The plan around that risk should already make clear who reviews it, whether further dosing is affected and when a broader safety review is required. Having that response defined doesn’t remove the clinical judgement, but it helps the team act consistently and promptly.

Tom

We’ve talked about strategy, studies, decisions, regulation and risk. How does the plan remain manageable across all the functions involved?

Jullia

Usually through two connected views. A high-level roadmap lets a steering committee, board member or new team member see the programme sequence and major decisions quickly. A supporting narrative explains the assumptions, the reasoning behind each study and how different results would affect the later plan.

Tom

I imagine those two versions can drift apart quite easily.

Jullia

They can, especially when timelines change quickly. That’s why the plan needs an owner, version control and a record of what changed and why. Reviews are often most useful after a data readout, regulatory interaction or major programme decision, rather than on a calendar date that has no connection to new information.

Tom

There’s also the question of realism. At what point do budgets and operational resources come into the plan?

Jullia

They need to be considered as the study sequence develops, then translated into a fully resourced timeline. That includes internal staff, CRO support, investigator sites, data management, manufacturing and drug supply, as well as the budget itself. A programme isn’t executable if the planned recruitment period, database work or regulatory preparation can’t be supported by the available people and systems.

Tom

Could linking resources to decision points help avoid committing too much too soon?

Jullia

Definitely. If investment is linked to defined milestones, the organisation can adjust its commitments as evidence emerges. For example, preparatory work for a later study may begin before a proof-of-concept readout, but the scale and timing of that work can reflect the probability of different outcomes rather than assuming the programme will progress unchanged.

Tom

For someone reviewing an existing CDP, what are the main takeaways they should carry into that review?

Jullia

First, check that every study answers a defined evidence need and supports a decision. Second, make sure the decision criteria are specific enough to guide action before the results are known. And finally, confirm that the regulatory, safety, operational and resourcing assumptions still reflect the programme as it stands today.

With that, we’ve come to the end of today’s episode on Clinical Development Plan. If you found this discussion useful, don’t forget to subscribe to QCast so you never miss an episode and share it with a colleague. And if you’d like to learn more about how Quanticate supports data-driven solutions in clinical trials, head to our website or get in touch.

Tom

Thanks for tuning in, and we’ll see you in the next episode.

About QCast

QCast by Quanticate is the podcast for biotech, pharma, and life science leaders looking to deepen their understanding of biometrics and modern drug development. Join co-hosts Tom and Jullia as they explore methodologies, case studies, regulatory shifts, and industry trends shaping the future of clinical research. Where biometric expertise meets data-driven dialogue, QCast delivers practical insights and thought leadership to inform your next breakthrough.

Subscribe to QCast on Apple Podcasts or Spotify to never miss an episode.